Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

S. De Placido; C. Gallo; M. De Laurentiis; G. Bisagni; G. Arpino; MG. Sarobba; F. Riccardi; A. Russo; L. Del Mastro; AA. Cogoni; F. Cognetti; S.  Gori; J. Foglietta; A. Frassoldati; D. Amoroso; L. Laudadio; L. Moscetti; F. Montemurro; C. Verusio; Antonio Bernardo; V. Lorusso; A. Gravina; G. Moretti; R. Lauria; A. Lai; C.  Mocerino; S. Rizzo; F. Nuzzo; P. Carlini; F. Perrone

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

S. De Placido, C. Gallo, M. De Laurentiis , G. Bisagni, G. Arpino, MG. Sarobba, F. Riccardi, A. Russo, L. Del Mastro, AA. Cogoni, F. Cognetti, S. Gori, J. Foglietta, A. Frassoldati, D. Amoroso, L. Laudadio, L. Moscetti, F. Montemurro, C. Verusio, Antonio BernardoV. Lorusso, A. Gravina, G. Moretti, R. Lauria, A. Lai, C. Mocerino, S. Rizzo, F. Nuzzo, P. Carlini, F. Perrone

Istituti Clinici Scientifici Maugeri Spa – Società Benefit

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	474-485
Number of pages	9
Journal	The Lancet Oncology
Publication status	Published - 2018

Cite this

De Placido, S., Gallo, C., De Laurentiis , M., Bisagni, G., Arpino, G., Sarobba, MG., Riccardi, F., Russo, A., Del Mastro, L., Cogoni, AA., Cognetti, F., Gori, S., Foglietta, J., Frassoldati, A., Amoroso, D., Laudadio, L., Moscetti, L., Montemurro, F., Verusio, C., ... Perrone, F. (2018). Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. The Lancet Oncology, 474-485.

De Placido, S, Gallo, C, De Laurentiis , M, Bisagni, G, Arpino, G, Sarobba, MG, Riccardi, F, Russo, A, Del Mastro, L, Cogoni, AA, Cognetti, F, Gori, S, Foglietta, J, Frassoldati, A, Amoroso, D, Laudadio, L, Moscetti, L, Montemurro, F, Verusio, C, Bernardo, A, Lorusso, V, Gravina, A, Moretti, G, Lauria, R, Lai, A, Mocerino, C, Rizzo, S, Nuzzo, F, Carlini, P & Perrone, F 2018, 'Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.', The Lancet Oncology, pp. 474-485.

@article{dae9ab0e062546df9e7c1d06152f56a1,

title = "Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.",

author = "{De Placido}, S. and C. Gallo and {De Laurentiis}, M. and G. Bisagni and G. Arpino and MG. Sarobba and F. Riccardi and A. Russo and {Del Mastro}, L. and AA. Cogoni and F. Cognetti and S. Gori and J. Foglietta and A. Frassoldati and D. Amoroso and L. Laudadio and L. Moscetti and F. Montemurro and C. Verusio and Antonio Bernardo and V. Lorusso and A. Gravina and G. Moretti and R. Lauria and A. Lai and C. Mocerino and S. Rizzo and F. Nuzzo and P. Carlini and F. Perrone",

year = "2018",

language = "English",

pages = "474--485",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

AU - De Placido, S.

AU - Gallo, C.

AU - De Laurentiis , M.

AU - Bisagni, G.

AU - Arpino, G.

AU - Sarobba, MG.

AU - Riccardi, F.

AU - Russo, A.

AU - Del Mastro, L.

AU - Cogoni, AA.

AU - Cognetti, F.

AU - Gori, S.

AU - Foglietta, J.

AU - Frassoldati, A.

AU - Amoroso, D.

AU - Laudadio, L.

AU - Moscetti, L.

AU - Montemurro, F.

AU - Verusio, C.

AU - Bernardo, Antonio

AU - Lorusso, V.

AU - Gravina, A.

AU - Moretti, G.

AU - Lauria, R.

AU - Lai, A.

AU - Mocerino, C.

AU - Rizzo, S.

AU - Nuzzo, F.

AU - Carlini, P.

AU - Perrone, F.

PY - 2018

Y1 - 2018

M3 - Article

SP - 474

EP - 485

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

ER -